Ozempic, Wegovy, and Zepbound are three brand names sitting on top of just two active drugs, and understanding that distinction is the single most useful thing to know before asking a doctor which one might fit your situation. This is not a guide for self-directing treatment — GLP-1 medications require a prescription, a doctor's evaluation, and ongoing monitoring, and nothing here should replace that conversation. What follows is what's publicly documented about how these three drugs differ on approval status, trial results, and cost in 2026, based on FDA labeling and manufacturer/pharmacy pricing pages.
The short version: Ozempic and Wegovy both contain semaglutide. Zepbound contains a different molecule, tirzepatide (the same active ingredient as Mounjaro). Only Wegovy and Zepbound are FDA-approved specifically for chronic weight management — Ozempic is approved for type 2 diabetes, and any weight-loss use of it is off-label. That single fact drives most of the confusion people run into with insurance coverage and pricing.
Quick Comparison Table
| Feature | Ozempic | Wegovy | Zepbound |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide |
| Manufacturer | Novo Nordisk | Novo Nordisk | Eli Lilly |
| FDA-approved for | Type 2 diabetes | Chronic weight management, cardiovascular risk reduction, MASH | Chronic weight management, obstructive sleep apnea |
| Weight-loss use | Off-label only | On-label | On-label |
| Avg. body weight loss (head-to-head trial, 72 weeks) | N/A (diabetes trials differ) | 13.7% (semaglutide) | 20.2% (tirzepatide) |
| List price (self-pay, monthly) | ~$349 via NovoCare | ~$349 injectable; oral from $149 | $299–$449 via LillyDirect |
| Insurance coverage pattern | Commonly covered for diabetes | Expanding, often requires prior authorization | Expanding, often requires prior authorization |
Same Molecule, Different Label: Ozempic vs. Wegovy
Ozempic and Wegovy are, chemically, the same drug — semaglutide — sold under two names because Novo Nordisk sought separate FDA approvals for two different uses. Ozempic was approved first for type 2 diabetes management. Wegovy came later, approved specifically for chronic weight management in people with obesity or overweight plus a weight-related condition, and has since picked up additional approvals for reducing cardiovascular risk and treating MASH (metabolic dysfunction-associated steatohepatitis).
This matters most at the pharmacy counter. Insurance plans generally look at the FDA label attached to the prescription, not the underlying molecule — so a semaglutide prescription written and coded for weight loss needs to go through Wegovy's approval pathway to have a realistic shot at coverage, even though it's the identical drug sold as Ozempic for diabetes.
Zepbound: A Different Molecule, and the Stronger Trial Results
Zepbound is where this comparison gets more interesting, because it isn't semaglutide at all — it's tirzepatide, a dual-action drug that targets both the GLP-1 and GIP receptors, versus semaglutide's single-receptor mechanism. The first major head-to-head randomized trial between the two molecules reported results in 2025: at 72 weeks, tirzepatide produced an average 20.2% body weight loss compared to 13.7% for semaglutide. Roughly one in three tirzepatide patients lost at least a quarter of their body weight, versus about one in six on semaglutide.
Zepbound has also picked up an FDA approval that neither Ozempic nor Wegovy currently holds: obstructive sleep apnea in adults with obesity. If sleep apnea is part of what's driving a weight-management conversation with a doctor, that's a relevant data point to bring up specifically.
Cost: The Number That Actually Varies the Most
List prices without insurance run roughly $900–$1,600 a month across this drug class, but almost nobody pays that figure — it mostly exists as the number every discount program is measured against. The realistic self-pay floor in 2026 looks more like this: Novo Nordisk's NovoCare program prices Wegovy and Ozempic around $349 a month (with a lower introductory rate), and an oral version of Wegovy starts around $149. Eli Lilly's LillyDirect program prices Zepbound vials between $299 and $449 depending on dose.
With commercial insurance and a manufacturer savings card, many patients land closer to $0–$25 a month — but that depends heavily on formulary tier, prior authorization, and whether the prescription is coded for an approved use. Coverage for weight-loss indications specifically (as opposed to diabetes) remains the most inconsistent part of this picture across insurers, and it's worth confirming directly with your plan rather than assuming.
Side Effects: Broadly Similar Across the Class
All three drugs share a similar side-effect profile, largely gastrointestinal: nausea, vomiting, diarrhea, constipation, and reduced appetite are the most commonly reported, especially during dose increases. Because dosing for all three typically starts low and increases gradually under a doctor's supervision, individual tolerance and the right starting point are exactly the kind of decisions that need a clinician's involvement rather than a fixed answer here. Rare but serious risks associated with this drug class — including pancreatitis and gallbladder issues — are covered in each drug's FDA-approved labeling, which is worth reading in full before starting treatment.
Availability and the Compounding Question
During the semaglutide and tirzepatide shortages, compounded versions from telehealth providers and compounding pharmacies became a common lower-cost alternative. That legal pathway has narrowed significantly in 2026 as the FDA has moved to remove these drugs from its shortage list, which removes the regulatory basis that allowed mass compounding. Several compounding pharmacies have challenged this in court, and the legal landscape has continued shifting through the year — anyone currently using a compounded version should treat this as an actively moving situation rather than a settled one.
Who Typically Fits Which
| Situation | Likely relevant option to discuss with a doctor |
|---|---|
| Diagnosed with type 2 diabetes | Ozempic (on-label) — Wegovy or Zepbound if weight loss is also a treatment goal |
| Weight management is the primary goal, insurance coverage matters | Wegovy (on-label, broadest cardiovascular/MASH approvals) |
| Weight management, prioritizing the strongest trial-reported results | Zepbound (higher average weight loss in head-to-head data) |
| Also diagnosed with obstructive sleep apnea and obesity | Zepbound (only one with this specific FDA approval) |
| Cost-sensitive, want the lowest self-pay entry point | Oral Wegovy or Zepbound's lower-dose vials — compare current manufacturer programs |
Frequently Asked Questions
Are Ozempic and Wegovy actually the same drug?
Yes, the active ingredient in both is semaglutide, made by Novo Nordisk. Ozempic is FDA-approved for type 2 diabetes; Wegovy is FDA-approved specifically for chronic weight management, at a higher maintenance dose.
Is Zepbound stronger than Wegovy?
In the first head-to-head randomized trial reported in 2025, tirzepatide (Zepbound's active ingredient) produced greater average weight loss than semaglutide (Wegovy's active ingredient) at 72 weeks — 20.2% versus 13.7%. Individual results vary, and a doctor can help weigh this against other factors like side effects and cost.
Can I get Ozempic prescribed for weight loss instead of Wegovy?
It happens off-label, but insurance coverage is far less predictable for that use since Ozempic's FDA approval is for diabetes, not weight management. Wegovy's on-label approval for weight loss generally gives it a more consistent path through insurance formularies for that specific purpose.
How much do these cost without insurance in 2026?
Manufacturer self-pay programs bring Wegovy and Ozempic to around $349/month through NovoCare (with a lower introductory rate), oral Wegovy from about $149/month, and Zepbound vials from $299–$449/month through LillyDirect. Retail cash price without any program can run $900–$1,600/month.
Are compounded versions of these drugs still available?
Availability has narrowed significantly in 2026 as the FDA has worked to remove these drugs from its shortage list, which is the regulatory basis that previously allowed mass compounding. Legal challenges are ongoing, so anyone relying on a compounded version should check current status directly with their pharmacy or provider.
What are the most common side effects?
Gastrointestinal effects — nausea, vomiting, diarrhea, and constipation — are the most commonly reported across all three drugs, particularly during dose increases. A full list of risks, including rarer serious ones, is available in each drug's FDA labeling and should be reviewed with a prescribing doctor.
This article is for general information only and is not medical advice. For official prescribing information, see the FDA label for Wegovy, the Ozempic official site, and the Zepbound official site. Always consult a licensed healthcare provider before starting or changing any prescription medication.